SLC9A9-AS1: A Potential Drug Target and Biomarker (G100885796)

Target Name: SLC9A9-AS1

NCBI ID: G100885796

SLC9A9-AS1

Other Name(s): SLC9A9 antisense RNA 1

SLC9A9-AS1: A Potential Drug Target and Biomarker

Sodium-dependent chromogranin A (SLC9A9) is a gene that encodes a protein known as AS1. The AS1 protein is expressed in various tissues and cells throughout the body and is involved in the production of collagen, a protein that is responsible for maintaining the structure and strength of connective tissue. The SLC9A9 gene has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular diseases, and neurodegenerative disorders.

The SLC9A9 gene was first identified in 2003 as a potential gene that could serve as a drug target for cancer. The SLC9A9 gene has been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, studies have shown that inhibition of the AS1 protein has been effective in treating various types of cancer, including cancer cell lines and animals.

The SLC9A9 gene has also been identified as a potential biomarker for cancer. The AS1 protein is expressed in various types of cancer cells and has been shown to be involved in the development and progression of cancer. Additionally, studies have shown that decreased levels of AS1 protein are associated with poor prognosis in cancer patients.

The SLC9A9 gene has also been shown to be involved in the development and progression of neurodegenerative disorders. The AS1 protein has been shown to be involved in the production of neurotransmitters, such as dopamine and serotonin, which are involved in the function of the nervous system. Additionally, studies have shown that decreased levels of AS1 protein are associated with the progression of neurodegenerative disorders.

In addition to its potential drug target and biomarker properties, the SLC9A9 gene has also been shown to have potential therapeutic applications in other areas. The AS1 protein has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. Additionally, the AS1 protein has been shown to be involved in the regulation of cell survival, which is the process by which cells decide when to die and be replaced.

In conclusion, the SLC9A9 gene has been shown to be a potential drug target and biomarker for various diseases. The AS1 protein has been shown to be involved in the production of collagen, the regulation of cell adhesion and survival, and the development and progression of cancer and neurodegenerative disorders. Further research is needed to fully understand the potential therapeutic applications of the SLC9A9 gene and its protein.

Protein Name: SLC9A9 Antisense RNA 1

The "SLC9A9-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC9A9-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets